Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

摘要: Background. Previous observations have suggested that leiomyosarcomas, and especially gastrointestinal may be less responsive to cancer chemotherapy than other histologic types of non-osseous sarcomas; however, this difference has not been characterized well until quite recently, with the recognition special identity stromal tumors (GIST). Prior general acceptance new classification, we decided study patients leiomyosarcomas in concert for relative responsivity a combination cytotoxic regimen developed specifically leiomyosarcomas.Patients Methods. Adult advanced received intravenous as outpatients dacarbazine 750 μg/m2, mitomycin 6 mg/m2, doxorubicin 40 cisplatin 60 mg/m2 on day 0, granulocyte macrophage colony stimulating factor (GM-CSF, sargramostim) 250 mcg/m2 given SC every 12 hr days −6 −3 day...